ZYUS Life Sciences Corporation ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -32.53% | 11.96% | -47.44% | -15.52% | 0.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -32.53% | 11.96% | -47.44% | -15.52% | 0.58% |
| Cost of Revenue | 1.90% | 29.79% | -83.98% | 107.61% | -6.58% |
| Gross Profit | -57.92% | -4.07% | 87.97% | -105.57% | 6.62% |
| SG&A Expenses | -26.87% | -8.88% | 0.97% | -6.92% | -25.66% |
| Depreciation & Amortization | -75.75% | -73.92% | -20.01% | -0.70% | -8.04% |
| Other Operating Expenses | -93.42% | -95.32% | -60.48% | -83.33% | -65.92% |
| Total Operating Expenses | -43.61% | -28.77% | -11.57% | -18.04% | -15.28% |
| Operating Income | 43.95% | 30.12% | 10.52% | 18.13% | 15.68% |
| Income Before Tax | 31.15% | 19.09% | 58.93% | 8.80% | 9.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.15% | 19.09% | 55.08% | 8.40% | 9.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.15% | 19.09% | 55.08% | 8.40% | 9.07% |
| EBIT | 43.95% | 30.12% | 10.52% | 18.13% | 15.68% |
| EBITDA | 37.41% | 19.04% | 8.50% | 22.40% | 17.10% |
| EPS Basic | 35.46% | 24.80% | 57.85% | 15.08% | 14.72% |
| Normalized Basic EPS | 35.23% | 25.00% | -3.48% | 15.60% | 15.11% |
| EPS Diluted | 33.41% | 21.29% | 57.87% | 8.79% | 15.23% |
| Normalized Diluted EPS | 35.23% | 25.00% | -3.48% | 15.60% | 15.11% |
| Average Basic Shares Outstanding | 6.49% | 7.76% | 6.63% | 7.97% | 6.73% |
| Average Diluted Shares Outstanding | 6.49% | 7.76% | 6.63% | 7.97% | 6.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |